You are here » Home » Companies » Company Overview »

.

BSE: N.A. Sector: N.A.
NSE: N.A. ISIN Code: N.A.
BSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN
PREVIOUS CLOSE
VOLUME
52-Week high
52-Week low
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high
52-Week low
P/E
Mkt Cap.(Rs cr) 0
Buy Price
Buy Qty
Sell Price
Sell Qty

. () - Chairman Speech

Company chairman speech

JUPITER BIOSCIENCE LIMITED ANNUAL REPORT 2010-2011 CHAIRMAN'S REPORT Dear Shareholder, The past financial year was an exceptional year considering the industry scenario and uncertain global economy. During the past year, your company continued its growth path by launching Generic Peptide APIs, APIs based on organic chemistry and Chiral Intermediates which strengthened its product pipeline. Your company's progress and achievement during the year indicated the progress and fulfillment of goals and objectives. During the financial year, the company fortified its presence in the regulatory markets through its subsidiaries located in Switzerland and USA. The sales for the year was Rs. 253.10 Crores which was 37.60% increase over the previous year. The Profit after tax for the year was Rs. 37.59 Crores which was 13.44% increase over the previous year. Hence your company is on the growth path. Your company is well-equipped for the slow but positive development in our markets with a diverse product portfolio of more than 400products which includes Peptide Building Blocks and APIs, High end Intermediates and APIs based on Organic Chemistry which was further expanded in the year under review. Your company remains fully committed to its vision and long-term strategy. We continue to invest significantly in Research and Development to strengthen our position in Peptides and Generic products and create new business opportunities. Warm regards Venkat R. Kalavakolanu Chairman & Managing Director